(100) Incorporating enzymatic activity into in vitro analysis of biotransformable drugs

Introduction: All classes of biotransformable drugs (prodrugs) are typically analyzed in dissolution apparatuses[1] that do not include the machinery required to catalyze the biotransformation. With 94% of prodrugs relying on the patient’s enzymatic activity,[2] we looked to include these constituents within our Subcutaneous Injection Site Simulator (SCISSOR) platform,[3,4] designed to probe the pharmacokinetic properties of injectable drugs. Herein, we describe the successful integration of enzymes within the platform and the ways in which this methodology can be used to analyze the release of prodrugs.